Abstract
As an exploratory study, our findings suggest that patients may not derive benefit from intraoperative radiotherapy. These observations are intended to lay the groundwork for future prospective clinical studies.
Introduction
Retroperitoneal liposarcoma (RPL) is a rare but aggressive malignancy arising from adipose tissue in the posterior abdomen. Due to the proximity of vital organs and major vasculature, achieving negative surgical margins is often difficult. While radiotherapy is frequently employed to improve outcomes, the specific role of Intraoperative Radiotherapy (IORT) has remained controversial. IORT theoretically offers a precision advantage by delivering radiation directly to the tumor bed while sparing adjacent healthy tissue. This study evaluates whether this technical advantage translates into a survival benefit.
Methodology
Researchers conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database, identifying 2,129 patients diagnosed with RPL between 2000 and 2019. To address potential selection bias—where patients receiving IORT might differ significantly from those who do not—the team employed Propensity Score Matching (PSM). This technique created two balanced groups (33 patients each) for a rigorous head-to-head comparison of overall survival (OS).
Key Findings
The study identified several independent prognostic factors for RPL, including age, tumor grade, histology, and tumor size. Notably, high-grade tumors (FNCLCC III) were associated with nearly double the risk of death compared to low-grade tumors (HR = 1.979).
Regarding the primary intervention, the analysis found no statistically significant difference in overall survival between patients who received IORT and those who did not (p = 0.711). This lack of benefit persisted even when IORT was combined with preoperative or postoperative external beam radiation.
Discussion and Limitations
The findings suggest that the "technical elegance" of IORT does not necessarily alter the systemic progression of RPL. Biological factors, particularly tumor grade and histology, appear to be far more dominant drivers of patient outcomes.
However, the study has limitations. The sample size for the IORT group was small (less than 1% of the total cohort), which may limit the power to detect minor survival differences. Additionally, the SEER database does not provide data on local recurrence or specific surgical margin status (R0 vs. R1). While IORT may not improve overall survival, its potential role in enhancing local control remains a subject for future prospective, randomized controlled trials.
Conclusion
Current evidence does not support IORT as a standard therapy for retroperitoneal liposarcoma. While it remains an exploratory option, clinicians should prioritize established prognostic factors when determining treatment strategies.
Summary updated